Hepatocellular carcinoma: Molecular aspects in hepatitis B

Viral Hepatitis

Volumn , Issue , 2007, Pages 269-294

  Buendia, Marie Annick ^a   Paterlini Bréchot, Patricia ^b   Tiollais, Pierre ^a   Bréchot, Christian ^b  

^a INSTITUT PASTEUR   (France)

^b INSERM   (France)

Author keywords

Diabetes mellitus; HBV genome; Hepadnaviruses; Hepatitis B virus (HBV); Hepatocellular carcinoma (HCC)

Indexed keywords

EID: 79958793216     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987131.ch17     Document Type: Chapter

References (334)

1. Beasley RP, Lin CC, Hwang LY, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22, 707 men in Taiwan. Lancet 1981;2:1129-33.
2. Szmuness W. Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association. Prog Med Virol 1978;24:40-69.
3. Schödel F, Sprengel R, Weimer T, Fernholz D, Schneider R, Will H. Animal hepatitis B viruses. In: Klein G, ed. Advances in Viral Oncology. New York: Raven Press, 1989:73-102.
4. Buendia MA. Hepatitis B viruses and hepatocellular carcinoma. Adv Cancer Res 1992;59:167-226.
5. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P, Chisari FV. Immune pathogenesis of hepatocellular carcinoma. J Exp Med 1998;188:341-50.
6. Chisari FV, Klopchin K, Moriyama T et al. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989;59:1145-56.
7. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991;351:317-20.
8. Dejean A, Bougueleret L, Grzeschik KH, Tiollais P. Hepatitis B virus DNA integration in a sequence homologous to v-erbA and steroid receptor genes in a hepatocellular carcinoma. Nature 1986;322:70-2.
9. Graef E, Caselmann WH, Wells J, Koshy R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994;9:81-7.
10. Wang J, Chenivesse X, Henglein B, Bréchot C. Hepatitis B virus integration in a cyclin A gene in a human hepatocellular carcinoma. Nature 1990;343:555-7.
11. Gozuacik D, Murakami Y, Saigo K et al. Identification of human cancer-related genes by naturally occurring hepatitis B virus DNA tagging. Oncogene 2001;20:6233-40.
12. Paterlini-Brechot P, Saigo K, Murakami Y et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene. Oncogene 2003;22:3911-16.
13. Hsu TY, Möröy T, Etiemble J et al. Activation of c-myc by woodchuck hepatitis virus insertion in hepatocellular carcinoma. Cell 1988;55:627-35.
14. Fourel G, Couturier J, Wei Y, Apiou F, Tiollais P, Buendia MA. Evidence for long-range oncogene activation by hepadnavirus insertion. EMBO J 1994;13:2526-34.
15. Bergametti F, Sitterlin D, Transy C. Turnover of hepatitis B virus X protein is regulated by damaged DNA-binding complex. J Virol 2002;76:6495-501.
16. Wei Y, Fourel G, Ponzetto A, Silvestro M, Tiollais P, Buendia MA. Hepadnavirus integration: mechanisms of activation of the N-myc2 retrotransposon in woodchuck liver tumors. J Virol 1992;66:5265-76.
17. Fourel G, Trépo C, Bougueleret L et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990;347:294-8.
18. Transy C, Fourel G, Robinson WS, Tiollais P, Marion PL, Buendia MA. Frequent amplification of c-myc in ground squirrel liver tumors associated with past or ongoing infection with a hepadnavirus. Proc Natl Acad Sci USA 1992;89:3874-8.
19. Testut P, Renard CA, Terradillos O et al. A new hepadnavirus endemic in arctic ground squirrels in Alaska. J Virol 1996;70:4210-19.
20. Tanaka K, Hirohata S, Koga S et al. Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population. Cancer Res 1991;51:2842-7.
21. Sun CA, Wu DM, Lin CC et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12, 008 men in Taiwan. Am J Epidemiol 2003;157:674-82
22. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50.
23. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37(Suppl. 8)):S4-S66.
24. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000. BMC Cancer 2002;2:37.
25. Hollinger FB. Hepatitis B virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. Philadelphia: Lippincott-Raven, 1996:2738-808.
26. Tabor E. Strongly supported features of the association between hepatitis B virus and hepatocellular carcinoma. Adv Appl Biotechnol Ser 1991;13:107-18.
27. Bosch FX, Munòz N. Hepatocellular carcinoma in the world:epidemiologic questions. Adv Appl Biotechnol Ser 1991;13:35-56.
28. Bréchot C, Jaffredo F, Lagorce D et al. Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 1998;29:173-83.
29. Hassan MM, Hwang LY, Hatten CJ et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology 2002;36:1206-13.
30. Beasley RP. Hepatitis B virus- the major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
31. Craig JR, Klatt EC, Yu M. Role of cirrhosis and the development of HCC: evidence from histologic studies and large population studies. Adv Appl Biotechnol Ser 1991;13:177-90.
32. Kew MC. Role of cirrhosis in hepatocarcinogenesis. In: Bannasch P, Keppler D, Weber G, eds. Liver Cell Carcinoma. Dordrecht, The Netherlands: Kluwer Academic Publishers, 1989:37-45.
33. Sun CA, Wu DM, Lin CC et al. Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12, 008 men in Taiwan. Am J Epidemiol 2003;157:674-82.
34. Iijima T, Saitoh N, Nobutomo K, Nambu M, Sakuma K. A prospective cohort study of hepatitis B surface antigen carriers in a working population. Gann 1984;75:571-3.
35. Chen CJ, Liang KY, Chang AS et al. Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology 1991;13:398-406.
36. Lok ASF, Lai CL, Chung H, Lau JYN, Leung EKY, Wong LSK. Morbidity and mortality from chronic hepatitis B virus infection in family members of patients with malignant and non-malignant hepatitis B virus-related chronic liver diseases. Hepatology 1991;13:834-7.
37. Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
38. Chang MH, Hsu C, Lee CY, Chen DS, Lee CH, Lin KS. Fraternal hepatocellular carcinoma in young children in two families. Cancer 1984;53:1807-10.
39. Yeh FS, Yu MC, Mo CC, Luo S, Tong MJ, Henderson BE. Hepatitis B virus, aflatoxins and hepatocellular carcinoma in southern Guangxi, China. Cancer Res 1989;49:2506-9.
40. Ming L, Thorgeirsson SS, Gail MH et al. Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology 2002;36:1214-20.
41. Austin H. The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. Adv Appl Biotechnol Ser 1991;13:57-76.
42. Bréchot C, Degos F, Lugassy C et al. Hepatitis B virus DNA in patients with chronic liver disease and negative test for hepatitis B surface antigen. N Engl J Med 1985;312:270-6.
43. Takase S, Takada N, Enomoto N, Yasuhara M, Takada A. Different types of chronic hepatitis in alcoholic patients:does chronic hepatitis induced by alcohol exist? Hepatology 1991;13:876-81.
44. Chiba T, Matsuzaki Y, Abei M et al. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996;91:1195-203.
45. El-Serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States Veterans. Am J Gastroenterol 2001;96:2462-7.
46. Oliveri F, Brunetto MR, Baldi M et al. Hepatitis delta virus (HDV) infection and hepatocellular carcinoma. In: Gerin JL, Purcell RH, Rizetto M, eds. The Hepatitis Delta Virus. New York:Wiley-Liss, 1991:217-22.
47. Okuda K. Hepatitis C virus and hepatocellular carcinoma. Adv Appl Biotechnol Ser 1991;13:119-26.
48. Takano S, Yokosuda O, Imazeki F. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995;21:650-5.
49. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002;36(5 Suppl. 1)):S74-S83.
50. Fourel G, Tiollais P. Molecular biology of hepatitis B virus. In:Bréchot C, ed. Primary Liver Cancer: Etiological and Progression Factors. Boca Raton: CRC Press, 1994:89-123.
51. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979;281:646-50.
52. Pasek M, Goto T, Gilbert W et al. Hepatitis B virus genes and their expression in Escherichia coli. Nature 1979;282:575-9.
53. Valenzuela P, Quiroga M, Zaldivar J, Gray J, Rutter WJ. The nucleotide sequence of the hepatitis B virus genome and the identification of the major viral genes. In: Fields B, Jaenisch R, Fox CF, eds. Animal Virus Genetics. New York: Academic Press, 1980:57-70.
54. Toh H, Hyashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983;305:827-9.
55. Kremsdorf D, Bréchot C. Genetic variability of hepatitis B virus:potential clinical implications. In: Bréchot C, ed. Primary Liver Cancer: Etiological and Progression Factors. Boca Raton:CRC Press, 1994:149-65.
56. Akarka US, Lok ASF. Naturally occuring hepatitis B virus mutants. Hepatology 1995;22:50-60.
57. Blum HE, Liang TJ, Galun E, Wands JR. Persistence of hepatitis B virus DNA after serological recovery from hepatitis B virus infection. Hepatology 1991;14:56-63.
58. Thiers V, Nakajima E, Kremsdorf D et al. Transmission of hepatitis B from hepatitis B seronegative subjects. Lancet 1988:1273-6.
59. Tran A, Kremsdorf D, Capel F et al. Emergence of and takeover by hepatitis B virus (HBV) with rearrangements in the pre-S/S and pre-C/C genes during chronic HBV infection. J Virol 1991;65:3566-74.
60. Wands JR, Fujita YK, Isselbacher KJ et al. Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci USA 1986;83:6608-12.
61. Hasegawa K, Huang J, Rogers SA, Blum HE, Liang TJ. Enhanced replication of hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. J Virol 1994;68:1651-9.
62. Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E. A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991;324:1705-9.
63. Omata M, Ehata T, Yokosuka O, Hosoda K, Ohto M. Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med 1991;324:1699-1704.
64. Gerken G, Kremsdorf D, Capel F et al. Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. Virology 1991;183:555-65.
65. Okamoto H, Imai M, Kametani M, Nakamura T, Mayumi M. Genomic heterogeneity of hepatitis B virus in a 54-year-old woman who contracted the infection through materno-fetal transmission. Jpn J Exp Med 1987;57:231-6.
66. Rosmorduc O, Petit MA, Pol S. In vivo and in vitro expression of defective hepatitis B virus particles generated by spliced hepatitis B virus RNA. Hepatology 1995;21:10-19.
67. Terré S, Petit MA, Bréchot C. Defective hepatitis B virus particles are generated by packaging and reverse transcription of spliced viral RNAs in vivo. J Virol 1991;65:5539-43.
68. Neurath AR, Kent SBH, Strick N, Parker K. Identification and chemical synthesis of a host cell receptor binding site on hepatitis B virus. Cell 1986;46:429-36.
69. Arii M, Takada S, Koike K. Identification of three essential regions of hepatitis B virus X protein for trans-activation function. Oncogene 1992;7:397-403.
70. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 1990;64:613-60.
71. Takada S, Koike K. Trans-activation function of a 3' truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc Natl Acad Sci USA 1990;87:5628-32.
72. Summers JA, O’Connell A, Millman I. Genome of hepatitis B virus: restriction enzyme cleavage and structure of DNA extracted from Dane particles. Proc Natl Acad Sci USA 1975;72:4597-601.
73. Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986;232:477-84.
74. Will H, Reiser W, Weimer T et al. Replication strategy of human hepatitis B virus. J Virol 1987;61:904-11.
75. Cattaneo R, Will H, Schaller H. Hepatitis B virus transcription in the infected liver. EMBO J 1984;3:2191-6.
76. Gough NM. Core and E antigen synthesis in rodent cells transformed with hepatitis B virus DNA is associated with greater than genome length viral messenger RNAs. J Mol Biol 1983;165:683-99.
77. Iijima T, Saitoh N, Nobutomo K, Nambu M, Sakuma K. A prospective cohort study of hepatitis B surface antigen carriers in a working population. Gann 1984;75:571-3.
78. Siddiqui A, Jameel S, Mapoles JE. Transcriptional control elements of hepatitis B surface antigen gene. Proc Natl Acad Sci USA 1986;83:566-70.
79. Treinin M, Laub O. Identification of a promoter element located upstream from the hepatitis B virus X gene. Mol Cell Biol 1987;7:545-8.
80. Doitsh G, Shaul Y. A long HBV transcript encoding pX is inefficiently exported from the nucleus. Virology 2003;309:339-49.
81. Buscher M, Reiser W, Will H, Schaller H. Transcripts and the putative RNA pregenome of duck hepatitis B virus:implications for reverse transcription. Cell 1985;40:717-24.
82. Enders GH, Ganem D, Varmus H. Mapping the major transcripts of ground squirrel hepatitis virus: the presumptive template for reverse transcriptase is terminally redundant. Cell 1985;42:297-308.
83. Möröy T, Etiemble J, Trépo C, Tiollais P, Buendia MA. Transcription of woodchuck hepatitis virus in the chronically infected liver. EMBO J 1985;4:1507-14.
84. Shaul Y, Rutter WJ, Laub O. A human hepatitis B viral enhancer element. EMBO J. 1985;4:427-30.
85. Yee JK. A liver-specific enhancer in the core promoter region of human hepatitis B virus. Science 1989;246:658-61.
86. Flajolet M, Fourel G, Wei Y et al. Hepatocellular carcinoma in the woodchuck. In: Rizzetto M, Purcell RH, Gerin JL, Verme G, eds. Viral Hepatitis and Liver Diseases. Turin: Edizioni Minerva Medica, 1997:509-14.
87. Fourel G, Ringeisen F, Flajolet M et al. The HNF-1/HNF-4- dependent WE2 element of woodchuck hepatitis virus controls viral replication and can activate the N-myc2 promoter. J Virol 1996;70:8571-83.
88. Lilienbaum A, Crescenzo-Chaigne B, Sall AA, Pillot J, Elfassi E. Binding of nuclear factors to functional domains of the duck hepatitis B virus enhancer. J Virol 1993;67:6192-200.
89. Liu C, Mason WS, Burch JBE. Idenfication of factor-binding sites in the duck hepatitis B virus enhancer and in vivo effects of enhancer mutations. J Virol 1994;68:2286-96.
90. Ueda K, Wei Y, Ganem D. Activation of N-myc2 gene expression by cis-acting elements of oncogenic hepadnavirus genomes: key role of enhancer II. Virology 1996;217:413-17.
91. Ueda K, Wei Y, Ganem D. Cellular factors controlling the activity of woodchuck hepatitis virus enhancer II. J Virol 1996;70:4714-23.
92. Miller RH, Robinson WS. Common evolutionary origin of hepatitis B virus and retroviruses. Proc Natl Acad Sci USA 1986;83:2531-5.
93. Moriarty AM, Alexander H, Lerner RA. Antibodies to peptides detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma. Science 1985;227:429-33.
94. Kay A, Mandart E, Trepo C, Galibert F. The HBV HBx gene expressed in E. coli is recognized by sera from hepatitis patients. EMBO J. 1985;4:1287-92.
95. Oda M, Tsuda F, Scarpa A, Sakamoto M, Hirohashi S. p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res 1992;52:6358-64.
96. Meyers ML, Vitvitski Trépo L, Nath N, Sninsky JJ. Hepatitis B virus polypeptide X: expression in Escherichia coli and identification of specific antibodies in sera from hepatitis B virus-infected humans. J Virol 1986;57:101-9.
97. Pfaff E, Salfeld J, Gmelin K, Schaller H, Theilmann L. Synthesis of the X protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera. Virology 1987;158:456-60.
98. Vitvitski-Trepo L, Kay A, Pichoud C et al. Early and frequent detection of HBxAg and/or anti-HBxAg in hepatitis B virus infection. Hepatology 1990;12:1278-83.
99. Haruna Y, Hayashi N, Katamaya K et al. Expression of X protein and hepatitis B virus replication in chronic hepatitis. Hepatology 1991;13:417-21.
100. Levrero M, Stemler M, Pasquinelli C et al. Significance of anti-HBx antibodies in hepatitis B virus infection. Hepatology 1991;13:143-9.
101. Wang W, London WT, Lega L, Feitelson MA. HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology 1991;14:29-37.
102. Dandri M, Schirmacher P, Rogler CE. Woodchuck hepatitis virus X protein is present in chronically infected woodchuck liver and in woodchuck hepatocellular carcinomas which are permissive for viral replication. J Virol 1996;70:5246-54.
103. Su Q, Schröder CH, Hofman WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinoma. Hepatology 1998;27:1109-20.
104. Wang HP, Rogler CE. Topoisomerase I-mediated integration of hepadnavirus DNA in vitro. J Virol 1991;65:2381-92.
105. Takada S, Shirakata Y, Kaneniwa N, Koike K. Association of hepatitis B virus X protein with mitochondria causes mitochondrial aggregation at the nuclear periphery, leading to cell death. Oncogene 1999;18:6965-73.
106. Waris G, Huh KW, Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol Cell Biol 2001;21:7721-30.
107. Doria M, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 1995;14:4747-57.
108. Höhne M, Schaefer S, Seifer M, Feitelson MA, Paul D, Gerlich WH. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J 1990;9:1137-45.
109. Hafner A, Brandenburg B, Hildt E. Reconstitution of gene expression from a regulatory-protein-deficient hepatitis B virus genome by cell-permeable HBx protein. EMBO Rep 2003;4:767-73.
110. Nomura T, Lin Y, Dorjsuren D, Ohno S, Yamashita T, Murakami S. Human hepatitis B virus X protein is detectable in nuclei of transfected cells, and is active for transactivation. Biochim Biophys Acta 1999;1453:330-40.
111. Weil R, Sirma H, Giannini C et al. Direct association and nuclear import of the hepatitis B virus X protein with the NF-kappaB inhibitor IkappaBalpha. Mol Cell Biol 1999;19:6345-54.
112. Forgues M, Difilippantonio MJ, Linke SP et al. Involvement of Crm1 in hepatitis B virus X protein-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 2003;23:5282-92.
113. Chen HS, Kanado S, Girones R et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 1993;67:1218-26.
114. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994;68:2026-30.
115. Rossner MT. Hepatitis B virus X-gene product: a promiscuous transcriptional transactivator. J Med Virol 1992;36:101-17.
116. Andrisani OM, Barnabas S. The transcriptional function of the hepatitis B virus X protein and its role in hepatocarcinogenesis. Int J Oncol 1999;15:373-9.
117. Murakami S. Hepatitis B virus X protein: structure, function and biology. Intervirology 1999;42:81-99.
118. Hafner A, Brandenburg B, Hildt E. Reconstitution of gene expression from a regulatory-protein-deficient hepatitis B virus genome by cell-permeable HBx protein. EMBO Rep 2003;4:767-73.
119. Yaginuma K, Kobayashi H, Kobayashi M, Morishima T, Matsuyama K, Koike K. Multiple integration site of hepatitis B virus DNA in hepatocellular carcinoma and chronic active hepatitis tissues from children. J Virol 1987;61:1808-13.
120. Balsano C, Avantaggiati ML, Natoli G et al. Transactivation of c-fos and c-myc protooncogenes by both full-length and truncated versions of the HBV-X protein. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. Proceedings of the 1990 International Symposium on Viral Hepatitis and Liver Disease: Contemporary Issues and Future Prospects. Baltimore, MD: Williams & Wilkins, 1991:572-6.
121. Colgrove R, Simon G, Ganem D. Transcriptional activation of homologous and heterologous genes by the hepatitis B virus X gene product in cells permissive for viral replication. J Virol 1989;63:4019-26.
122. Spandau DF, Lee CH. Trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol 1988;62:427-34.
123. Twu JS, Schloemer RH. Transcriptional trans-activating function of hepatitis B virus. J Virol 1987;61:3448-53.
124. Lucito R, Schneider RJ. Hepatitis B virus X protein activates transcription factor NF-κB without a requirement for protein kinase C. J Virol 1992;66:983-91.
125. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by proteinprotein interactions. Science 1991;252:842-4.
126. Williams JS, Andrisam OM. The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB. Proc Natl Acad Sci USA 1995;92:3819-23.
127. Lee YI, Lee S, Lee Y et al. The human hepatitis B virus transactivator X gene product regulates Sp1 mediated transcription of an insulin-like growth factor II promoter 4. Oncogene 1998;16:2367-80.
128. Cheong J, Yi M, Lin Y, Murakami S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J 1995;14:143-50.
129. Haviv I, Vaizel D, Shaul Y. The X protein of hepatitis B virus coactivates potent activation domains. Mol Cell Biol 1995;15:1079-85.
130. Qadri I, Maguire HF, Siddiqui A. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci USA 1995;92:1003-7.
131. Haviv I, Shamay M, Doitsh O, Shaul Y. Hepatitis B virus pX targets TFIIB in transcription coactivation. Mol Cell Biol 1998;18:1562-9.
132. Qadri I, Conaway JW, Conaway RC, Schaack J, Siddiqui A. Hepatitis B virus transactivator protein, HBx, associates with the components of TFIIH and stimulates the DNA helicase activity of TFIIH. Proc Natl Acad Sci USA 1996;93:10578-83.
133. Shamay M, Barak O, Doitsh G, Ben-Dor I, Shaul Y. Hepatitis B virus pX interacts with HBXAP, a PHD finger protein to coactivate transcription. J Biol Chem 2002;277:9982-8.
134. Seto E, Mitchell PJ, Yen TSB. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 1990;344:72-4.
135. Benn J, Su F, Doria M, Schneider RJ. Hepatitis B virus HBx protein induces transcription factor AP-1 by activation of extracellular signal-regulated and c-jun N-terminal mitogenactivated protein kinases. J Virol 1996;70:4978-85.
136. Natoli G, Avantaggiati ML, Chirillo P et al. Ras and Rafdependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994;9:2837-43.
137. Tarn C, Lee S, Hu Y, Ashendel C, Andrisani OM. Hepatitis B virus X protein differentially activates RAS-RAF-MAPK and JNK pathways in X-transforming versus non-transforming AML12 hepatocytes. J Biol Chem 2001;276:34671-80.
138. Doria M, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 1995;14:4747-57.
139. Chirillo P, Falco M, Puri PL et al. Hepatitis B virus pX activates NF-κB-dependent transcription through a Raf-independent pathway. J Virol 1996;70:641-6.
140. Lara-Pezzi E, Armesilla AL, Majano PL, Redondo JM, Lopez-Cabrera M. The hepatitis B virus X protein activates nuclear factor of activated T cells (NF-AT) by a cyclosporin A-sensitive pathway. EMBO J 1998;17:7066-77.
141. Su P, Schneider RJ. Hepatitis B virus HBx protein activates transcription factor NF-KB by acting on multiple cytoplasmic inhibitors of rel-related proteins. J Virol 1996;70:4558-66.
142. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition of p53 response element-directed transactivation. J Virol 1995;69:1851-9.
143. Prost S, Ford JM, Taylor C, Doig J, Harrison DJ. Hepatitis Bx protein inhibits p53-dependent DNA repair in primary mouse hepatocytes. J Biol Chem 1998;273:33327-32.
144. Takada S, Kaneniwa N, Tsuchida N, Koike K. Cytoplasmic retention of the p53 tumor suppressor gene product is observed in the hepatitis B virus X gene-transfected cells. Oncogene 1997;15:1895-901.
145. Lee TH, Elledge SJ, Butel JS. Hepatitis B virus X protein interacts with a probable DNA repair protein. J Virol 1995;69:1107-14.
146. Becker SA, Lee TH, Butel JS, Slagle BL. Hepatitis B virus X protein interferes with cellular DNA repair. J Virol 1998;72:266-72.
147. Bontron S, Lin-Marq N, Strubin M. Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2. J Biol Chem 2002;277:38847-54.
148. Leupin O, Bontron S, Strubin M. Hepatitis B virus X protein and simian virus 5 V protein exhibit similar UV-DDB1 binding properties to mediate distinct activities. J Virol 2003;77:6274-83.
149. Madden CR, Slagle BL. Stimulation of cellular proliferation by hepatitis B virus X protein. Dis Markers 2001;17:153-7.
150. Sirma H, Weil R, Rosmorduc O et al. Cytosol is the prime compartment of hepatitis B virus X protein where it colocalizes with the proteasome. Oncogene 1998;16:2051-63.
151. Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001;294:2376-8.
152. Klein NP, Bouchard MJ, Wang LH, Kobarg C, Schneider RJ. Src kinases involved in hepatitis B virus replication. EMBO J 1999;18:5019-27.
153. Chami M, Ferrari D, Nicotera P, Paterlini-Bréchot P, Rizzuto R. Caspase-dependent alterations of Ca2+ signaling in the induction of apoptosis by hepatitis B virus X protein. J Biol Chem 2003;278:31745-55.
154. Kim H, Lee H, Yun Y. X-gene product of hepatitis B virus induces apoptosis in liver cells. J Biol Chem 1998;273:381-5.
155. Kim KH, Seong BL. Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal. EMBO J 2003;22:2104-16.
156. Shintani Y, Yotsuyanagi H, Moriya K et al. Induction of apoptosis after switch-on of the hepatitis B virus X gene mediated by the Cre/loxP recombination system. J Gen Virol 1999;80(Pt 12)):3257-65.
157. Shirakata Y, Koike K. Hepatitis B virus X protein induces cell death by causing loss of mitochondrial membrane potential. J Biol Chem 2003;278:22071-8.
158. Su F, Schneider RJ. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis alpha. Proc Natl Acad Sci USA 1997;94:8744-9.
159. Su F, Theodosis CN, Schneider RJ. Role of NF-kappaB and myc proteins in apoptosis induced by hepatitis B virus HBx protein. J Virol 2001;75:215-25.
160. Schuster R, Hildt E, Chang SF et al. Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses. Oncogene 2002;21:6606-13.
161. Elmore LW, Hancock AR, Chang S-F et al. Hepatitis B virus X protein and p53 tumor suppressor interactions in the modulation of apoptosis. Proc Natl Acad Sci USA 1997;94:14707-12.
162. Pan J, Duan LX, Sun BS, Feitelson MA. Hepatitis B virus X protein protects against anti-Fas-mediated apoptosis in human liver cells by inducing NF-kappaB. J Gen Virol 2001;82(Pt 1)):171-82.
163. Shih WL, Kuo ML, Chuang SE, Cheng AL, Doong SL. Hepatitis B virus X protein inhibits transforming growth factor-beta-induced apoptosis through the activation of phosphatidylinositol 3- kinase pathway. J Biol Chem 2000;275:25858-64.
164. Wang XW, Gibson MK, Vermeulen W et al. Abrogation of p53- induced apoptosis by the hepatitis B virus X gene. Cancer Res 1995;55:6012-16.
165. Shirakata Y, Kawada M, Fujiki Y et al. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jpn J Cancer Res 1989;80:617-21.
166. Gottlob K, Pagano S, Levrero M, Graessmann A. Hepatitis B virus X protein transcription activation domains are neither required nor sufficient for cell transformation. Cancer Res 1998;58:3566-70.
167. Kim YC, Song KS, Yoon G, Nam MJ, Ryu WS. Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene 2001;20:16-23.
168. Schuster R, Gerlich WH, Schaefer S. Induction of apoptosis by the transactivating domains of the hepatitis B virus X gene leads to suppression of oncogenic transformation of primary rat embryo fibroblasts. Oncogene 2000;19:1173-80.
169. Koike K, Moriya K, Lino S et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994;19:810-19.
170. Billet O, Grimber G, Levrero M, Seye KA, Briand P, Joulin V. In vivo activity of the hepatitis B virus core promoter tissue specificity and temporal regulation. J Virol 1995;69:5912-16.
171. Lee TH, Finegold MJ, Shen RF, DeMayo JL, Woo SLC, Butel JS. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990;64:5939-47.
172. Yen BTS. Hepadnaviral X protein: review of recent progress. J Biomed Sci 1996;3:20-30.
173. Slagel BL, Lee TH, Medina D, Finegold MJ, Butel JS. Increased sensitivity to the hepatocarcinogen diethylnitrosamine in transgenic mice carrying the hepatitis B virus X gene. Mol Carcinog 1996;15:261-9.
174. Terradillos O, Billet O, Renard CA et al. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997;14:395-404.
175. Madden CR, Finegold MJ, Slagle BL. Altered DNA mutation spectrum in aflatoxin b1-treated transgenic mice that express the hepatitis B virus x protein. J Virol 2002;76:11770-4.
176. Yoo YG, Oh SH, Park ES et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003;278:39076-84.
177. Terradillos O, Pollicino T, Lecoeur H et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998;17:2115-23.
178. Tralhao JG, Roudier J, Morosan S et al. Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis. Proc Natl Acad Sci USA 2002;99:6991-6.
179. Ou JH, Rutter WJ. Hybrid hepatitis B virus-host transcripts in a human hepatoma cell. Proc Natl Acad Sci USA 1985;82:83-7.
180. Nagaya T, Nakamura T, Tokino T. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev 1983;1:773-82.
181. Shih C, Burke K, Chou MJ et al. Tight clustering of human hepatitis B virus integration sites in hepatomas near a triplestranded region. J Virol 1987;61:3491-8.
182. Tu H, Bonura C, Giannini C, Mouly H et al. Biological impact of natural COOH-terminal deletions of hepatitis B virus X protein in hepatocellular carcinoma tissues. Cancer Res 2001;61:7803-10.
183. Wang Y, Lau SH, Sham JS, Wu MC, Wang T, Guan XY. Characterization of HBV integrants in 14 hepatocellular carcinomas:association of truncated X gene and hepatocellular carcinogenesis. Oncogene 2004;23:142-8.
184. Wollersheim M, Debelka U, Hofschneider PH. A transactivating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 1988;3:545-52.
185. Koshy R, Wells J. Deregulation of cellular gene expression by HBV transactivators in hepatocarcinogenesis. Adv Appl Biotechnol Ser 1991;13:159-70.
186. Sirma H, Giannini C, Poussin K, Paterlini P, Kremsdorf D, Brechot C. Hepatitis B virus X mutants, present in hepatocellular carcinoma tissue abrogate both the antiproliferative and transactivation effects of HBx. Oncogene 1999;18:4848-59.
187. Poussin K, Dienes H, Sirma H et al. Expression of mutated hepatitis B virus X genes in human hepatocellular carcinomas. Int J Cancer 1999;80:497-505.
188. Yeh CT, Shen CH, Tai DI, Chu CM, Liaw YF. Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma. Oncogene 2000;19:5213-20.
189. Huo TI, Wang XW, Forgues M et al. Hepatitis B virus X mutants derived from human hepatocellular carcinoma retain the ability to abrogate p53-induced apoptosis. Oncogene 2001;20:3620-8.
190. Babinet C, Farza H, Morello D, Hadchouel M, Pourcel C. Specific expression of hepatitis B surface antigen (HBsAg) in transgenic mice. Science 1985;230:1160-3.
191. Chisari FV, Pinckert CA, Milich DR et al. A transgenic mouse model of the chronic hepatitis B surface antigen carrier state. Science 1985;230:1157-9.
192. Farza H, Hadchouel M, Scotto J, Tiollais P, Babinet C, Pourcel C. Replication and gene expression of hepatitis B virus in a transgenic mouse that contains the complete viral genome. J Virol 1988;62:4144-52.
193. Guidotti LG, Matzke B, Schaller H, Chisari FV. High-level hepatitis B virus replication in transgenic mice. J Virol 1995;69:6158-9.
194. Chisari FV, Filippi P, McLachlan A et al. Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol 1986;60:880-7.
195. Hagen TM, Huang SM, Curnutte J et al. Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 1994;91:12808-12.
196. Huang S, Chisari FV. Strong, sustained hepatocellular proliferation precedes hepatocarcinogenesis in hepatitis B surface antigen transgenic mice. Hepatology 1995;21:620-6.
197. Teeter LD, Becker FF, Chisari FV, Li D, Kuo MT. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. Mol Cell Biol 1990;10:5728-35.
198. Kekulé AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The pre-S2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990;343:457-61.
199. Lauer U, Weiss L, Hofschneider PH, Kekulé AS. The hepatitis B virus pre-S/St transactivator is generated by 3' truncations within a defined region of the S gene. J Virol 1992;66:5284-9.
200. Hildt E, Munz B, Saher G, Reifenberg K, Hofschneider PH. The PreS2 activator MHBs(t) of hepatitis B virus activates craf-1/Erk2 signaling in transgenic mice. EMBO J 2002;21:525-35.
201. Bréchot C, Pourcel C, Louise A, Rain B, Tiollais P. Presence of integrated hepatitis B virus DNA sequences in cellular DNA of human hepatocellular carcinoma. Nature 1980;286:533-5.
202. Chakraborty PR, Ruiz Opazo H, Shouval D, Shafritz DA. Identification of integrated hepatitis B virus DNA and expression of viral RNA in an HBsAg-producing human hepatocellular carcinoma cell line. Nature 1980;286:531-3.
203. Edman JC, Gray P, Valenzuela P, Rall LB, Rutter WJ. Integration of hepatitis B virus sequences and their expression in a human hepatoma cell. Nature 1980;286:535-7.
204. Lugassy C, Bernuau J, Thiers V et al. Sequences of hepatitis B virus DNA in the serum and liver of patients with acute benign and fulminant hepatitis. J Infect Dis 1987;155:64-71.
205. Ochiya T, Tsurimoto T, Ueda K, Okubo K, Shiozawa M, Matsubara K. An in-vitro system for infection with hepatitis B virus that uses primary human fetal hepatocytes. Proc Natl Acad Sci USA 1989;86:1875-9.
206. Boender PJ, Schalm SW, Heijtink RA. Detection of integration during active replication of hepatitis B virus in the liver. J Med Virol 1985;16:47-54.
207. Tanaka Y, Esumi M, Shikata T. Frequent integration of hepatitis B virus DNA in noncancerous liver tissue from hepatocellular carcinoma patients. J Med Virol 1988;26:7-14.
208. Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol Biol Med 1990;7:243-260.
209. Chang MH, Chen PJ, Chen JY et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology 1991;13:316-20.
210. Koshy R, Koch S, Freytag von Loringhoven A, Kahmann R, Murray K, Hofschneider PH. Integration of hepatitis B virus DNA: evidence for integration in the single-stranded gap. Cell 1983;34:215-23.
211. Tsuei DJ, Chang MH, Chen PJ, Hsu TY, Ni YH. Characterization of integration patterns and flanking cellular sequences of hepatitis B virus in childhood hepatocellular carcinomas. J Med Virol 2002;68:513-21.
212. Hino O, Ohtake K, Rogler CE. Features of two hepatitis B virus (HBV) DNA integrations suggest mechanisms of HBV integration. J Virol 1989;63:2638-43.
213. Dejean A, Sonigo P, Wain-Hobson S, Tiollais P. Specific hepatitis B virus integration in hepatocellular carcinoma DNA through a viral 11 base pair direct repeat. Proc Natl Acad Sci USA 1984;81:5350-4.
214. Zhou YZ, Butel JS, Li PJ, Finegold MJ, Melnick JL. Integrated state of subgenomic fragments of hepatitis B virus DNA in hepatocellular carcinoma from mainland China. J Natl Cancer Inst 1987;79:223-231.
215. Bréchot C, Gozuacik D, Murakami Y, Paterlini-Bréchot P. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000;10:211-31.
216. Bushman FD. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. Cell 2003;115:135-8.
217. Fourel G, Trépo C, Bougueleret L et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990;347:294-8.
218. Wang J, Zindy F, Chenivesse X, Lamas E, Henglein B, Bréchot C. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene 1992;7:1653-6.
219. Desdouets C, Sobczak-Thepot J, Murphy M, Bréchot C. Cyclin A: function and expression during cell proliferation. Prog Cell Cycle Res 1995;1:115-23.
220. Berasain C, Patil D, Perara E, Huang SM, Mouly H, Bréchot C. Oncogenic activation of a human cyclin A2 targeted to the endoplasmic reticulum upon hepatitis B virus genome insertion. Oncogene 1998;16:1277-88.
221. Paterlini P, Bréchot C. Hepatitis B virus and primary liver cancer in hepatitis B surface antigen-positive and -negative patients. In: Bréchot C, ed. Primary Liver Cancer: Etiological and Progression Factors. Boca Raton: CRC Press, 1994:167-90.
222. Paterlini P, Driss F, Nalpas B et al. Persistence of hepatitis B and hepatitis C viral genomes in primary liver cancers from HBsAg-negative patients: a study of a low-endemic area. Hepatology 1993;17:20-9.
223. Chami M, Gozuacik D, Saigo K et al. Hepatitis B virus-related insertional mutagenesis implicates SERCA1 gene in the control of apoptosis. Oncogene 2000;19:2877-86.
224. Ferber MJ, Montoya DP, Yu C et al. Integrations of the hepatitis B virus (HBV) and human papillomavirus (HPV) into the human telomerase reverse transcriptase (hTERT) gene in liver and cervical cancers. Oncogene 2003;22:3813-20.
225. Horikawa I, Barrett JC. cis-Activation of the human telomerase gene (hTERT) by the hepatitis B virus genome. J Natl Cancer Inst 2001;93:1171-3.
226. Hino O, Shows TB, Rogler CE. Hepatitis B virus integration site in hepatocellular carcinoma at chromosome 17;18 translocation. Proc Natl Acad Sci USA 1986;83:8338-42.
227. Tokino T, Fukushige S, Nakamura T et al. Chromosomal translocation and inverted duplication associated with integrated hepatitis B virus in hepatocellular carcinomas. J Virol 1987;61:3848-54.
228. Yaginuma K, Kobayashi M, Yoshida E, Koike K. Hepatitis B virus integration in hepatocellular carcinoma DNA: duplication of cellular flanking sequences at the integration site. Proc Natl Acad Sci USA 1985;82:4458-62.
229. Hino O, Tabata S, Hotta Y. Evidence for increased in vitro recombination with insertion of human hepatitis B virus DNA. Proc Natl Acad Sci USA 1991;88:9248-52.
230. Slagle BL, Zhou YZ, Butel JS. Hepatitis B virus integration event in human chromosome 17p near the p53 gene identifies the region of the chromosome commonly deleted in viruspositive hepatocellular carcinomas. Cancer Res 1991;51:49-54.
231. Seeger C, Baldwin B, Hornbuckle WE et al. Woodchuck hepatitis virus is a more efficient oncogenic agent than ground squirrel hepatitis virus in a common host. J Virol 1991;65:1673-9.
232. Marion PL, Van Davelaar MJ, Knight SS et al. Hepatocellular carcinoma in ground squirrels persistently infected with ground squirrel hepatitis virus. Proc Natl Acad Sci USA 1986;83:4543-6.
233. Fourel G, Transy C, Tennant BC, Buendia MA. Expression of the woodchuck N-myc2 retroposon in brain and in liver tumors is driven by a cryptic N-myc promoter. Mol Cell Biol 1992;12:5336-44.
234. Bruni R, Argentini C, D’Ugo E, Giuseppetti R, Ciccaglione AR, Rapicetta M. Recurrence of WHV integration in the b3n locus in woodchuck hepatocellular carcinoma. Virology 1995;214:229-34.
235. Bruni R, D’Ugo E, Giuseppetti R, Argentini C, Rapicetta M. Activation of the N-myc2 oncogene by woodchuck hepatitis virus integration in the linked downstream b3n locus in woodchuck hepatocellular carcinoma. Virology 1999;257:483-90.
236. D’Ugo E, Bruni R, Argentini C, Giuseppetti R, Rapicetta M. Identification of scaffold/matrix attachment region in recurrent site of woodchuck hepatitis virus integration. DNA Cell Biol 1998;17:519-27.
237. Etiemble J, Degott C, Renard CA et al. Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion. Oncogene 1994;9:727-37.
238. Renard CA, Fourel G, Bralet MP et al. Hepatocellular carcinoma in WHV/N-myc 2 transgenic mice: Oncogenic mutations of beta-catenin and synergistic effect of p53 null alleles. Oncogene 2000;19:2678-86.
239. Etiemble J, Möröy T, Jacquemin E, Tiollais P, Buendia MA. Fused transcripts of c-myc and a new cellular locus, hcr, in a primary liver tumor. Oncogene 1989;4:51-7.
240. Möröy T, Marchio A, Etiemble J, Trépo C, Tiollais P, Buendia MA. Rearrangement and enhanced expression of c-myc in hepatocellular carcinoma of hepatitis virus infected woodchucks. Nature 1986;324:276-9.
241. Saunders JB, Wodak AD, Morgan-Capner P et al. Importance of markers of hepatitis B virus in alcoholic liver disease. BMJ 1983;286:1851-4.
242. Bréchot C. Hepatitis B virus (HBV) and hepatocellular carcinoma, HBV status and its implication. J Hepatol 1987;4:269-79.
243. Kew M, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin Liver Dis 1984;4:136-45.
244. Tabor E. Hepatocellular carcinoma: possible etiologies in patients without serologic evidence of hepatitis B virus infection. J Med Virol 1989;27:1-6.
245. Hsia CC, Scudamore CH, Di Bisceglie AM, Tabor E. Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. J Med Virol 2003;70:20-6.
246. Colombo M. Hepatocellular carcinoma. J Hepatol 1992;15:225-36.
247. Nalpas B, Driss F, Pol S et al. Association between HCV and HBV infection in hepatocellular carcinoma and alcoholic liver disease. J Hepatol 1991;12:70-4.
248. Pol S, Thiers V, Nalpas B et al. Monoclonal anti-HBs antibodies radioimmunoassay and serum HBV-DNA hybridization as diagnostic tools of HBV infection: relative prevalence among HBsAg-negative alcoholics, patients with chronic hepatitis or hepatocellular carcinomas and blood donors. Eur J Clin Invest 1987;17:515-21.
249. Marcellin P, Thiers V, Degott C et al. Hepatocellular carcinoma with normal adjacent liver hepatitis B virus DNA status. J Hepatol 1989;8:249-253.
250. Pontisso P, Stanico D, Diodati G et al. HBV DNA sequences are rarely detected in the liver of patients with HBsAg negative chronic active liver disease and with hepatocellular carcinoma in Italy. Liver 1987;7:211-15.
251. Pontisso P, Basso G, Perilongo G et al. Does hepatitis B virus play a role in primary liver cancer in children of western countries? Cancer Detect Prev 1991;15:363-8.
252. Walter E, Blum H, Meier P et al. Hepatocellular carcinoma in alcoholic liver disease: no evidence for a pathogenetic role of hepatitis B virus infection. Hepatology 1988;8:745-8.
253. Cobden I, Bassendine M, James O. Hepatocellular carcinoma in North-East England: importance of hepatitis B infection and ex-tropical military service. Q J Med 1986;60:855-63.
254. Dunk A, Spiliadis H, Sherlock S et al. Hepatocellular carcinoma:clinical, aetiological and pathological features in British patients. Int J Cancer 1988;41:17-23.
255. White YS, Johnson PJ, Davison F, Williams R. Frequency of hepatic HBV-DNA in patients with cirrhosis and hepatocellular carcinoma: relation to serum HBV markers. Br J Cancer 1990;61:909-12.
256. Fong T, Govindarajan S, Valinluck B, Redeker A. Status of hepatitis B virus DNA in alcoholic liver disease: a study of a large urban population in the united states. Hepatology 1988;8:1602-4.
257. Hino O, Kitagawa T, Sugano H. Relationship between serum and histochemical markers for hepatitis B virus and rate of viral integration in hepatocellular carcinomas in Japan. Int J Cancer 1985;35:5-10.
258. Hino O, Kitagawa T, Koike K et al. Detection of hepatitis B virus DNA in hepatocellular carcinomas in Japan. Hepatology 1984;4:90-5.
259. Koike K, Yaginuma K, Mizusawa H, Kobayashi M. Structure of integrated HBV DNA in human hepatomas. In: Nishioka K, Blumberg BS, Ishida N, Koike K, eds. Hepatitis Viruses and Hepatocellular Carcinoma Approaches through Molecular Biology and Ecology. Tokyo: Academic Press, 1985:99-115.
260. Horiike N, Michitaka K, Onji M, Murota T, Ohta Y. HBV DNA hybridization in hepatocellular carcinoma associated with alcohol in Japan. J Med Virol 1989;28:189-92.
261. Chen C, Diani A, Brown P, Kaluzny M, Epps D. Hepatocellular detection of hepatitis B virus DNA in hepatocellular carcinoma. Br J Exp Pathol 1986;67:1868.
262. Hsu HC, Chiou TJ, Chen JY, Lee CS, Lee PH, Peng SY. Clonality and clonal evolution of hepatocellular carcinoma with multiple nodules. Hepatology 1991;13:923-8.
263. Lok A, Ma O. Hepatitis B virus replication in Chinese patients with hepatocellular carcinoma. Hepatology 1990;12:582-8.
264. Lai M, Chen P, Yang P, Sheu J, Sung J, Chen D. Identification and characterization of intrahepatic hepatitis B virus DNA in HBsAg-seronegative patients with chronic liver disease and hepatocellular carcinoma in Taïwan. Hepatology 1990;3:575-81.
265. Shafritz D, Kew M. Identification of integrated hepatitis B virus DNA sequences in human hepatocellular carcinomas. Hepatology 1981;1:1-8.
266. Bréchot C, Kremsdorf D, Paterlini P, Thiers V. Hepatitis B virus DNA in HBsAg-negative patients. Molecular characterization and clinical implications. J Hepatol 1991;13:S49-S55.
267. Marion PL. Ground squirrel hepatitis virus. In: McLachlan A, ed. Molecular Biology of the Hepatitis B Virus. Boca Raton: CRC Press, 1991:39-51.
268. Shimada S, Aizawa R, Abe H, Suto S, Miyakawa Y, Aizawa Y. Analysis of risk factors for hepatocellular carcinoma that is negative for hepatitis B surface antigen (HBsAg). Intern Med 2003;42:389-93.
269. Mendenhall CL, Seeff L, Diehl AM et al. Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. Hepatology 1991;14:581-9.
270. Pares A, Barrera JM, Caballeria J et al. Hepatitis C virus antibodies in chronic alcoholic patients association with severity of liver injury. Hepatology 1990;12:1295-9.
271. Attali P, Thibault N, Buffett C et al. Les marqueurs du virus B chez les alcooliques chroniques. Clin Biol 1981;5:1095-102 (in French).
272. Nalpas B, Berthelot P, Thiers V et al. Hepatitis B virus multiplication in the absence of usual serological markers. A study of 146 alcoholics. J Hepatol 1985;1:89-97.
273. Poynard T, Aubert A, Lazizi Y et al. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology 1991;13:896-901.
274. Paterlini P, Gerken G, Nakajima E et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med 1990;323:80-5.
275. Pontisso P, Morsica G, Ruvoletto MG et al. Latent hepatitis B virus infection in childhood hepatocellular carcinoma. Cancer 1992;69:2731-5.
276. Ruiz J, Sangro B, Guende JI et al. Hepatitis B and C viral infections in patients with hepatocellular carcinoma. Hepatology 1992;3:637-40.
277. Ohkoshi S, Kato N, Kinoshita T et al. Detection of hepatitis C virus RNA in sera and liver tissues of non-A, non-B hepatitis patients using the polymerase chain reaction. Jpn J Cancer Res 1990;81:862-5.
278. Coursaget P, Le Cann P, Leboulleux D, Diop MT, Bao O, Coll AM. Detection of hepatitis B virus DNA by polymerase chain reaction in HBsAg negative Senegalese patients suffering from cirrhosis or primary liver cancer. FEMS Microbiol Lett 1991;67:35-8.
279. Dazza MC, Meneses LV, Girard PM et al. Polymerase chain reaction for detection of hepatitis B virus DNA in HBsAg seronegative patients with hepatocellular carcinoma from Mozambique. Ann Trop Med Paraitol 1991;85:277-9.
280. Liang TJ, Jeffers L, Cheinquer H et al. Viral etiology of hepatocellular carcinoma in United States. Hepatology 1992;16:128A.
281. Bréchot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Bréchot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely ‘occult’? Hepatology 2001;34:194-203.
282. Korba BE, Wells FV, Baldwin B et al. Hepatocellular carcinoma in woodchuck hepatitis virus-infected woodchucks: presence of viral DNA in tumor tissue from chronic carriers and animals serologically recovered from acute infections. Hepatology 1989;9:461-70.
283. Unsal H, Yakicier C, Marçais C et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994;91:822-6.
284. Paterlini P, Gerken G, Khemeny F et al. Primary liver cancer in HBsAg-negative patients: a study of HBV genome using the polymerase chain reaction. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral Hepatitis and Liver Disease. USA: Williams & Wilkins, 1991:605-10.
285. Galloway DA, Mc Dougall JK. The oncogenic potential of herpes simplex viruses evidence for a ‘hit and run’ mechanism. Nature 1983;302:21-4.
286. Smith KT, Campo MS. ‘Hit and run’ transformation of mouse C127 cells by bovine papillomavirus type 4: the viral DNA is required for the initiation but not for maintenance of the transformed phenotype. Virology 1988;64:39-47.
287. Gong SS, Jensen AD, Rogler CE. Loss and acquisition of duck hepatitis B virus integrations in lineages of LMH-D2 chicken hepatoma cells. J Virol 1996;70:2000-7.
288. Giannini C, Brechot C. Hepatitis C virus biology. Cell Death Differ 2003;10(Suppl. 1)):S27-S38.
289. Sullivan DE, Gerber MA. Conservation of hepatitis C virus 5' untranslated sequence in hepatocellular carcinoma and the surrounding liver. Hepatology 1994;19:551-3.
290. Landford R, Chavez D, Vonchisari F, Sureau C. Lack of detection of negative-strand hepatitis C virus RNA in peripheral blood mononuclear cells and other extrahepatic tissues by the highly strand-specific rTth reverse transcriptase PCR. J Virol 1995;69:8079-83.
291. Nakamoto Y, Kaneko S. Mechanisms of viral hepatitis induced liver injury. Curr Mol Med 2003;3:537-44.
292. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. Oncogene 2003;22:5093-107.
293. De Mitri S, Poussin K, Baccarini P. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413-15.
294. Ray R, Lagging L, Meyer K, Steele R, Ray R. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Res 1995;37:209-20.
295. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998;4:1065-7.
296. Lerat H, Honda M, Beard MR et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002;122:352-65.
297. Moriya K, Nakagawa K, Santa T et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virusassociated hepatocarcinogenesis. Cancer Res 2001;61:4365-70.
298. Kim DW, Suzuki R, Harada T. Trans-suppression of gene expression by hepatitis C viral core protein. Jpn J Med Sci Biol 1994;47:211-20.
299. Shih CM, Chen CM, Chen SY, Lee YH. Modulation of the trans-suppression activity of hepatitis C virus core protein by phosphorylation. J Virol 1995;69:1160-70.
300. Barba G, Harper F, Harada T et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997;94:1200-5.
301. Lo SY, Masiarz F, Hwang SB, Lai MMC, Ou JH. Differential subcellular localization of hepatitis C virus core gene products. Virology 1995;213:455-61.
302. Delhem N, Sabile A, Gajardo R et al. Activation of the interferoninducible protein kinase PKR by hepatocellular carcinoma derived-hepatitis C virus core protein. Oncogene 2001;20:5836-45.
303. Horie C, Iwahana H, Horie T et al. Detection of different quasispecies of hepatitis C virus core region in cancerous and noncancerous lesions. Biochem Biophys Res Commun 1996;218:674-81.
304. Ruster B, Zeuzem S, Roth WK. Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. Biochem Biophys Res Commun 1996;219:911-15.
305. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001;98:9599-604.
306. Bréchot C. Hepatitis C virus: molecular biology and genetic variability. In: Schmid R, ed. Acute and Chronic liver Diseases. Basel, Switzerland: Kluwer Academic, 1996:35-57.
307. Nousbaum JB, Pol S, Nalpas B. Hepatitis C virus types 1b (II) infection in France and Italy. Ann Intern Med 1995;122:161-8.
308. Silini E, Bottelli R, Asti M et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a case-control study. Gastroenterology 1996;111:199-205.
309. Ogata N, Kamimura T, Asakura H. Point-mutation, allelic loss and increased methylation of c-Ha-Ras gene in human hepatocellular carcinoma. Hepatology 1991;13:31-7.
310. Tada M, Omata M, Ohto M. Analysis of ras gene mutations in human hepatic malignant tumors by polymerase chain reaction and direct sequencing. Cancer Res 1990;50:1121-4.
311. Boige V, Laurent-Puig P, Fouchet P et al. Concerted nonsyntenic allelic losses in hyperploid hepatocellular carcinoma as determined by a high-resolution allelotype. Cancer Res 1997;57:1986-90.
312. Nagai H, Pineau P, Tiollais P, Buendia MA, Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene 1997;14:2927-33.
313. Marchio A, Meddeb M, Pineau P et al. Recurrent chromosomal abnormalities in hepatocellular carcinoma detected by comparative genomic hybridization. Genes Chromosomes Cancer 1997;18:59-65.
314. Buendia MA. Genetics of hepatocellular carcinoma. Semin Cancer Biol 2000;10:185-200.
315. Wright JA, Smith HS, Watt FM, Hancock C, Hudson DL, Stark GR. DNA amplification is rare in normal human cells. Proc Natl Acad Sci USA 1990;87:1791-5.
316. Laurent-Puig P, Legoix P, Bluteau O et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001;120:1763-73.
317. Marchio A, Pineau P, Meddeb M et al. Distinct chromosomal abnormality pattern in primary liver cancer of non-B, non-C patients. Oncogene 2000;19:3733-8.
318. Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin Liver Dis 1999;19:235-42.
319. Staib F, Hussain SP, Hofseth LJ, Wang XW, Harris CC. TP53 and liver carcinogenesis. Hum Mutat 2003;21:201-16
320. Bressac B, Kew M, Wands J, Ozturk M. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-31.
321. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991;350:427-8.
322. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B induces the transversion of G-T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993;90:8586-90.
323. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994;264:1317-19.
324. Murakami Y, Hayashi K, Hirohashi S, Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma benes in human hepatocellular carcinoma. Cancer Res 1991;51:5520-5.
325. De Souza AT, Hankins GR, Washington MK, Orton TC, Jirtle RL. M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nat Genet 1995;11:447-9.
326. Liew CT, Li HM, Lo KW et al. Frequent allelic loss on chromosome 9 in hepatocellular carcinoma. Int J Cancer 1999;81:319-24.
327. Wei Y, Tran Van Nhieu J, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, β-catenin expression and clinical features. Hepatology 2002;36:692-701.
328. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003;163:1371-8.
329. Wei Y, Tran Van Nhieu J, Prigent S, Srivatanakul P, Tiollais P, Buendia MA. Altered expression of E-cadherin in hepatocellular carcinoma: correlations with genetic alterations, β-catenin expression and clinical features. Hepatology 2002;36:692-701.
330. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999;9:15-21.
331. Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm:Wnt signaling in cancer. Biochim Biophys Acta 2003;1653:1-24.
332. de La Coste A, Romagnolo B, Billuart P et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998;95:8847-51.
333. Tran van Nhieu J, Renard CA, Wei Y, Cherqui D, Zafrani ES, Buendia MA. Nuclear accumulation of mutated beta-catenin in hepatocellular carcinoma is associated with increased cell proliferation. Am J Pathol 1999;155:703-10.
334. Cagatay T, Ozturk M. P53 mutation as a source of aberrant betacatenin accumulation in cancer cells. Oncogene 2002;21:7971-80.